PubMed:10328107 / 0-214
Annnotations
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 35-56 | cell_type | denotes | malignant lymphocytes |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-135 | Sentence | denotes | Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 35-56 | NP | denotes | malignant lymphocytes |
| C2 | 78-94 | NP | denotes | arsenic trioxide |
| C3 | 98-134 | NP | denotes | clinically achievable concentrations |
| C4 | 148-172 | NP | denotes | Arsenic trioxide (As2O3) |
| R1 | C4 | C2 | coref-ident | Arsenic trioxide (As2O3),arsenic trioxide |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-9 | other_name | denotes | Apoptosis |
| T2 | 35-56 | cell_type | denotes | malignant lymphocytes |
| T3 | 78-94 | other_organic_compound | denotes | arsenic trioxide |
| T4 | 148-164 | other_organic_compound | denotes | Arsenic trioxide |
| T5 | 166-171 | other_organic_compound | denotes | As2O3 |
| T6 | 206-214 | multi_cell | denotes | patients |